Xiang Rong, Yu Zhengsen, Wang Yang, Wang Lili, Huo Shanshan, Li Yanbai, Liang Ruiying, Hao Qinghong, Ying Tianlei, Gao Yaning, Yu Fei, Jiang Shibo
College of Life Sciences, Hebei Agricultural University, Baoding 071001, China.
Research Center of Chinese Jujube, Hebei Agricultural University, Baoding 071001, China.
Acta Pharm Sin B. 2022 Apr;12(4):1591-1623. doi: 10.1016/j.apsb.2021.06.016. Epub 2021 Jul 2.
The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world. Even though several COVID-19 vaccines are currently in distribution worldwide, with others in the pipeline, treatment modalities lag behind. Accordingly, researchers have been working hard to understand the nature of the virus, its mutant strains, and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents. As the research continues, we now know the genome structure, epidemiological and clinical features, and pathogenic mechanism of SARS-CoV-2. Here, we summarized the potential therapeutic targets involved in the life cycle of the virus. On the basis of these targets, small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection.
由新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的2019冠状病毒病（COVID-19）大流行已在全球范围内造成严重破坏。尽管目前有几种COVID-19疫苗正在全球范围内分发，还有其他疫苗正在研发中，但治疗方式仍滞后。因此，研究人员一直在努力了解该病毒的性质、其突变株以及疾病的发病机制，以发现可能的药物靶点和有效的治疗药物。随着研究的继续，我们现在已经了解了SARS-CoV-2的基因组结构、流行病学和临床特征以及致病机制。在此，我们总结了病毒生命周期中涉及的潜在治疗靶点。基于这些靶点，小分子预防和治疗药物已经或正在被开发用于预防和治疗SARS-CoV-2感染。
